{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:41Z","timestamp":1793730941690,"version":"4.6.1"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.atherosclerosis.2025.119114","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T02:50:14Z","timestamp":1738119014000},"page":"119114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA"],"prefix":"10.1016","volume":"403","author":[{"given":"Eliot A.","family":"Brinton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda F.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.atherosclerosis.2025.119114_bib1","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1177\/2047487319888054","article-title":"Prevalence of familial chylomicronemia syndrome in a quaternary care center","volume":"27","author":"Pallazola","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacl.2020.01.014","article-title":"Chylomicronemia syndrome: familial or not?","volume":"14","author":"Warden","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2025.119114_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11154311","article-title":"Identifying patients with familial chylomicronemia syndrome using FCS score-based data mining methods","volume":"11","author":"N\u00e9meth","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib4","series-title":"Volanesorsen for Treating Familial Chylomicronaemia Syndrome","year":"2020"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib5","series-title":"Familial Lipoprotein Lipase Deficiency: National Organization for Rare Disorders","year":"2019"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacl.2018.03.021","article-title":"Prevalence of familial chylomicronemia syndrome (FCS): are we underestimating?","volume":"12","author":"Khavandi","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.10702","article-title":"Diagnosis and management of type I and type V hyperlipoproteinemia","volume":"19","author":"Gotoda","year":"2012","journal-title":"J. Atherosclerosis Thromb."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.119114_bib8","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119114_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jacl.2018.03.093","article-title":"Clinical and biochemical features of different molecular etiologies of familial chylomicronemia","volume":"12","author":"Hegele","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119114_bib10","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","article-title":"Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study","volume":"12","author":"Blom","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119114_bib11","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jacl.2018.04.009","article-title":"The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study","volume":"12","author":"Davidson","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.119114_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia-current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atherosclerosis Suppl."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.119114_bib14","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/ajg.2015.261","article-title":"Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis","volume":"110","author":"Nawaz","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score\"","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.119114_bib16","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1161\/ATVBAHA.119.313401","article-title":"Spectrum of mutations and long-term clinical outcomes in genetic chylomicronemia syndromes","volume":"39","author":"D'Erasmo","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib17","series-title":"Gene Reviews","article-title":"Familial lipoprotein lipase deficiency","author":"Burnett","year":"1999"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119114_bib18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib19","series-title":"Glybera [summary of Product Characteristics] WITHDRAWN","year":"2017"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.119114_bib20","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/hum.2015.158","article-title":"Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis","volume":"27","author":"Gaudet","year":"2016","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/humc.2013.087","article-title":"Lessons learned from the clinical development and market authorization of Glybera","volume":"24","author":"Bryant","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119114_bib23","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metabol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.119114_bib24","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"33","key":"10.1016\/j.atherosclerosis.2025.119114_bib25","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-Acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur. Heart J."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2025.119114_bib26","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.119114_bib28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14779072.2017.1372193","article-title":"The burden of familial chylomicronemia syndrome from the patients' perspective","volume":"15","author":"Gelrud","year":"2017","journal-title":"Expert Rev. Cardiovasc Ther."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.119114_bib29","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11136-022-03266-0","article-title":"Qualitative development of the PROMIS profile v1.0-familial chylomicronemia syndrome (FCS) 28","volume":"32","author":"Kaiser","year":"2023","journal-title":"Qual. Life Res."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.119114_bib31","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa056","article-title":"Dissection of clinical and gene expression signatures of familial versus multifactorial chylomicronemia","volume":"4","author":"Tremblay","year":"2020","journal-title":"J. Endocr. Soc."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119114_bib32","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1210\/clinem\/dgaa838","article-title":"10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes","volume":"106","author":"Belhassen","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.12.019","article-title":"Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia","volume":"283","author":"Paquette","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117489","article-title":"Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia","volume":"392","author":"Guay","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.886266","article-title":"The evolving story of multifactorial chylomicronemia syndrome","volume":"9","author":"Paquette","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119114_bib36","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jacl.2020.04.011","article-title":"Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association","volume":"14","author":"Brown","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.119114_bib37","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1210\/js.2019-00214","article-title":"Differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles","volume":"3","author":"O'Dea","year":"2019","journal-title":"J Endocr Soc"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.119114_bib38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","article-title":"Current knowledge of hypertriglyceridemic pancreatitis","volume":"25","author":"Valdivielso","year":"2014","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clinbiochem.2023.02.002","article-title":"Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity","volume":"114","author":"Brisson","year":"2023","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib40","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","author":"Hegele","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib41","series-title":"Genetic Testing and Counseling","year":"2023"},{"issue":"47","key":"10.1016\/j.atherosclerosis.2025.119114_bib42","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2091-2-1","article-title":"Plasma lipases and lipid transfer proteins increase phospholipid but not free cholesterol transfer from lipid emulsion to high density lipoproteins","volume":"2","author":"Nunes","year":"2001","journal-title":"BMC Biochem."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib45","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz059","article-title":"Body mass index, triglycerides, and risk of acute pancreatitis: a population-based study of 118 000 individuals","volume":"105","author":"Hansen","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/2013.jamainternmed.477","article-title":"Hypertriglyceridemia and acute pancreatitis","volume":"173","author":"Murphy","year":"2013","journal-title":"JAMA Intern. Med."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.119114_bib47","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119114_bib48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.beem.2013.10.002","article-title":"Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis","volume":"28","author":"Berglund","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MOL.0000000000000866","article-title":"Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia","volume":"34","author":"Hang","year":"2023","journal-title":"Curr. Opin. Lipidol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.119114_bib50","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib51","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.119114_bib52","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1194\/jlr.R120001116","article-title":"Chylomicronemia from GPIHBP1 autoantibodies","volume":"61","author":"Miyashita","year":"2020","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119114_bib53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib54","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jacl.2023.01.005","article-title":"Role of lipoprotein lipase activity measurement in the diagnosis of familial chylomicronemia syndrome","volume":"17","author":"Rioja","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.12.018","article-title":"Differential effects of volanesorsen on ApoC-III, triglycerides and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or non-genetic criteria","author":"Tsimikas","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MOL.0000000000000576","article-title":"The evolution of genetic-based risk scores for lipids and cardiovascular disease","volume":"30","author":"Dron","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12920-020-0669-2","article-title":"Six years' experience with Lipid Seq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias","volume":"13","author":"Dron","year":"2020","journal-title":"BMC Med. Genom."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.119114_bib58","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacl.2014.08.010","article-title":"Familial chylomicronemia syndrome and response to medium-chain triglyceride therapy in an infant with novel mutations in GPIHBP1","volume":"8","author":"Ahmad","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.119114_bib59","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid management in patients with endocrine disorders: an endocrine society clinical practice guideline","volume":"105","author":"Newman","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119114_bib60","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/ajg.2009.27","article-title":"Hypertriglyceridemic pancreatitis: presentation and management","volume":"104","author":"Tsuang","year":"2009","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119114_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052736","article-title":"Current advances in RNA therapeutics for human diseases","volume":"23","author":"Zogg","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: a review","volume":"296","author":"Crooke","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119114_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1594","article-title":"The powerful world of antisense oligonucleotides: from bench to bedside","volume":"11","author":"Quemener","year":"2020","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib64","series-title":"Drugs@FDA: FDA-Approved Drugs","year":"2023"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.119114_bib66","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib67","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/nar\/28.2.582","article-title":"Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides","volume":"28","author":"Lorenz","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119114_bib68","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jns.12519","article-title":"Liver-directed drugs for transthyretin-mediated amyloidosis","volume":"27","author":"Brannagan","year":"2022","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"18","key":"10.1016\/j.atherosclerosis.2025.119114_bib69","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1093\/nar\/gkv920","article-title":"The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA","volume":"43","author":"Vickers","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib70","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s42003-021-02772-0","article-title":"Antisense oligonucleotide activity in tumour cells is influenced by intracellular LBPA distribution and extracellular vesicle recycling","volume":"4","author":"Kapustin","year":"2021","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119114_bib71","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/nar\/gkad023","article-title":"Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics","volume":"51","author":"Finicle","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119114_bib72","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","article-title":"RNA interference in the era of nucleic acid therapeutics","volume":"42","author":"Jadhav","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119114_bib73","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/nar\/gky037","article-title":"Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo","volume":"46","author":"Hassler","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib74","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jimd.12251","article-title":"Opportunities and challenges for antisense oligonucleotide therapies","volume":"44","author":"Kuijper","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.119114_bib75","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1719565115","article-title":"Structurally modulated codelivery of siRNA and Argonaute 2 for enhanced RNA interference","volume":"115","author":"Li","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.119114_bib76","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbagrm.2013.07.008","article-title":"RNA helicase A is not required for RISC activity","volume":"1829","author":"Liang","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119114_bib77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1871529X11202020133","article-title":"Human apolipoprotein C-III - a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins","volume":"12","author":"Yao","year":"2012","journal-title":"Cardiovasc. Hematol. Disord.: Drug Targets"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2025.119114_bib78","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119114_bib79","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/ATVBAHA.122.317966","article-title":"Broadening the scope of dyslipidemia therapy by targeting APOC3 (apolipoprotein C3) and ANGPTL3 (angiopoietin-like protein 3)","volume":"43","author":"Ginsberg","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/ATVBAHA.118.311476","article-title":"Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism","volume":"39","author":"Reyes-Soffer","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2025.119114_bib81","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160607","article-title":"Postprandial metabolism of apolipoproteins B48, B100, C-III and E in humans with APOC3 loss-of-function mutations","volume":"7","author":"Taskinen","year":"2022","journal-title":"JCI Insight"},{"issue":"5908","key":"10.1016\/j.atherosclerosis.2025.119114_bib82","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119114_bib83","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119114_bib84","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib85","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/DDDT.S224771","article-title":"Volanesorsen in the treatment of familial chylomicronemia syndrome or hypertriglyceridaemia: design, development and place in therapy","volume":"14","author":"Esan","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib86","series-title":"FDA Briefing Document: EMDAC Meeting for Volanesorsen (Waylivra)","year":"2018"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib87","series-title":"Regulatory Decision Summary for Waylivra (Volanesorsen)","year":"2018"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.119114_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12092017","article-title":"Assessment of platelet aggregation and thrombin generation in patients with familial chylomicronemia syndrome treated with volanesorsen: a cross-sectional study","volume":"12","author":"Calcaterra","year":"2024","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119114_bib89","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.119114_bib90","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/nat.2020.0917","article-title":"Improvements in the tolerability profile of 2'-O-methoxyethyl chimeric antisense oligonucleotides in parallel with advances in design, screening, and other methods","volume":"31","author":"Partridge","year":"2021","journal-title":"Nucleic Acid Therapeut."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119114_bib91","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1172\/JCI125228","article-title":"Selective tissue targeting of synthetic nucleic acid drugs","volume":"129","author":"Seth","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.119114_bib92","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17425255.2019.1621838","article-title":"Pharmacokinetics and clinical pharmacology considerations of GalNAc(3)-conjugated antisense oligonucleotides","volume":"15","author":"Wang","year":"2019","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2025.119114_bib93","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib94","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2018.0753","article-title":"Integrated assessment of the clinical performance of GalNAc(3)-conjugated 2'-O-methoxyethyl chimeric antisense oligonucleotides: I. Human volunteer experience","volume":"29","author":"Crooke","year":"2019","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib95","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.omtn.2017.08.012","article-title":"Assessment of the drug interaction potential of unconjugated and GalNAc(3)-conjugated 2'-MOE-ASOs","volume":"9","author":"Shemesh","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib96","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/nat.2023.0026","article-title":"Safety and tolerability of GalNAc(3)-conjugated antisense drugs compared to the same-sequence 2'-O-methoxyethyl-modified antisense drugs: results from an integrated assessment of Phase 1 clinical trial data","volume":"34","author":"Baker","year":"2024","journal-title":"Nucleic Acid Therapeut."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib97","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/nat.2022.0044","article-title":"Integrated assessment of Phase 2 data on GalNAc(3)-conjugated 2'-O-methoxyethyl-modified antisense oligonucleotides","volume":"33","author":"Baker","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.119114_bib98","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119114_bib99","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib100","unstructured":"Onpattro [package Insert]. Cambridge, MA: Alnylam Pharmaceuticals; 2018 August 2018."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2025.119114_bib103","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119114_bib104","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcph.2337","article-title":"Pharmacokinetics and pharmacodynamics of GalNAc-conjugated siRNAs","volume":"64","author":"An","year":"2024","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.119114_bib105","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1124\/dmd.119.087098","article-title":"In vitro drug-drug interaction evaluation of GalNAc conjugated siRNAs against CYP450 enzymes and transporters","volume":"47","author":"Ramsden","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib106","series-title":"Carlsbad, CA: Ionis Pharmaceuticals","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib108","series-title":"A Study of Olezarsen (ISIS 678354) Administered to Participants with Severe Hypertriglyceridemia NCT05079919","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib109","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib112","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.119114_bib113","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200325","article-title":"RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia","volume":"2","author":"Gaudet","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib114","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib116","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","author":"Watts","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119114_bib117","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1152\/ajpendo.00195.2021","article-title":"Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8","volume":"321","author":"Sylvers-Davie","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.119114_bib118","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/ATVBAHA.108.182147","article-title":"Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids","volume":"29","author":"Kersten","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib119","series-title":"Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants with Familial Chylomicronemia Syndrome (FCS)","year":"2021"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119114_bib120","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.119114_bib121","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib122","series-title":"Evkeeza [package insert]","year":"2021"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2025.119114_bib123","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140989","article-title":"Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice","volume":"131","author":"Singh","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.119114_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100237","article-title":"ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy","volume":"63","author":"Deng","year":"2022","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib125","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvae195","article-title":"Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidemia and atherosclerosis development in APOE\u22173-Leiden.CETP mice","author":"Modder","year":"2024","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119114_bib126","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/HCO.0000000000000839","article-title":"Genetics of hypertriglyceridemia and atherosclerosis","volume":"36","author":"Gill","year":"2021","journal-title":"Curr. Opin. Cardiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.119114_bib127","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119114_bib128","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","journal-title":"J. Intern. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.119114_bib129","doi-asserted-by":"crossref","first-page":"883","DOI":"10.5551\/jat.RV17054","article-title":"Current diagnosis and management of primary chylomicronemia","volume":"28","author":"Okazaki","year":"2021","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib130","article-title":"A study comparing two subcutaneous formulations: vial and autoinjector (AI) with olezarsen, at two dose levels, in healthy adult participants","year":"2023","journal-title":"NCT05579860: ClinicalTrials.gov"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib133","series-title":"A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) NCT05681351","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib134","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","author":"Ballantyne","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib136","article-title":"A phase 3 study of VSA001 in Chinese adults with familial chylomicronemia syndrome","year":"2023","journal-title":"NCT05902598: ClinicalTrials.gov"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib137","series-title":"Phase 3 Study of Plozasiran in Adults with Hypertriglyceridemia (MUIR-3) NCT06347133","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2025.119114_bib138","series-title":"Study of Plozasiran (ARO-APOC3) in Adults with Severe Hypertriglyceridemia (SHASTA-3) NCT06347003","year":"2024"}],"updated-by":[{"DOI":"10.1016\/j.atherosclerosis.2025.119210","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000}}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T20:32:54Z","timestamp":1746217974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":130,"alternative-id":["S0021915025000115"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119114","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119114"}}